Logotype for ImpediMed Limited

ImpediMed (IPD) investor relations material

ImpediMed H2 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for ImpediMed Limited
H2 2025 earnings summary27 Aug, 2025

Executive summary

  • Achieved 23% year-over-year revenue growth to $12.7 million, driven by SOZO® system sales and recurring revenue in North America.

  • SOZO® Core business revenue grew 25% to $12.1 million, with annual recurring revenue (ARR) reaching $14.0 million.

  • Installed base expanded 14% globally to 1,139 units, with U.S. installations up 19%.

  • Record 287,000 patient tests in FY25, up 15% year-over-year, and 1.19 million cumulative tests since launch.

  • Expanded reimbursement coverage to 82% of the U.S. population, supporting further growth.

Financial highlights

  • Total revenue: $12.7 million (up 23% year-over-year); SOZO Core Business revenue: $12.1 million (up 25%).

  • Gross margin: 86% (down from 87% in FY24).

  • Net loss: $23.2 million (vs. $19.8 million in FY24), driven by lower finance/grant income and higher share-based payments.

  • Operating expenses: $35.2 million (up $2.2 million year-over-year); salaries and benefits reduced by $1.5 million.

  • Cash and cash equivalents: $22.2 million at year-end; net cash used in operations: $14.3 million (improved from $17.8 million in FY24).

  • SOZO Core Business TCV signed: $19.2 million (up from $9.6 million in FY24).

Outlook and guidance

  • Focus on accelerating revenue growth in breast cancer-related lymphoedema (BCRL) and expanding reimbursement.

  • Continued investment in sales, product development, and clinical adoption in heart failure and body composition.

  • Path to profitability through revenue growth and financial discipline.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next ImpediMed earnings date

Logotype for ImpediMed Limited
Q1 202619 Oct, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next ImpediMed earnings date

Logotype for ImpediMed Limited
Q1 202619 Oct, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

ImpediMed Limited is an Australian medical technology company specializing in bioimpedance spectroscopy (BIS) technology for non-invasive health assessments. The company’s primary products focus on the early detection, monitoring, and management of lymphedema, as well as body composition and fluid status assessments. ImpediMed’s technology is used in healthcare settings to support patient care in oncology, renal health, and other medical fields where fluid management is critical. ImpediMed Limited is headquartered in Brisbane, Australia, and its shares are listed on the ASX.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage